Correspondence

The use and harms of Cumyl-PeGaClone

Government response to the ACMD's review of the evidence on the use and harms of Cumyl-PeGaClone.

• From: Home Office, Advisory Council on the Misuse of Drugs and The Rt Hon Chris Philp MP
• Published: 25 July 2023

This was published under the 2022 to 2024 Sunak Conservative government

Documents

Government response to the ACMD’s advice on Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists

HTML

Details

A letter from the Minister of State for Crime, Policing and Fire to the Advisory Council on the Misuse of Drugs (ACMD), responding to the ACMD’s advice on the use and harms of Cumyl-PeGaClone.

Cumyl-PeGaClone is a synthetic cannabinoid receptor agonist (SCRA), which was added to schedule II of the Convention on Psychotropic Substances of 1971 during the 64th Commission on Narcotic Drugs (CND) meeting in April 2021.

In 2022, the government commissioned the ACMD to give advice on the appropriate classification and scheduling of Cumyl-PeGaClone under the Misuse of Drugs Act 1971, to which they responded with their report in May 2023.

Published 25 July 2023